← 返回前沿论文

纠正肿瘤相关 NK 细胞中的线粒体复合物 I 缺陷可增强胶质母细胞瘤的免疫治疗

英文原题:Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma.

PubMed 2026/09/01(内容时间) Cancer Discov Q1 · IF 29.5(JCR 2025)

研究概要

这些发现揭示了线粒体复合体I活性在NK细胞中的关键作用,并突出了其作为可操作靶点以增强NK细胞免疫疗法对GBM患者疗效的潜力。

中文摘要

尽管免疫肿瘤治疗在其他癌症中取得了成功,但在胶质母细胞瘤(GBM)中基本失败。在本研究中,来自胶质瘤患者的自然杀伤(NK)细胞显示出氧化磷酸化和线粒体复合物I活性受损。多组学分析鉴定出复合物I亚基NDUFA9是NK细胞代谢适应性的关键介质。NDUFA9+ NK细胞的丰度可预测患者预后。NK细胞中Ndufa9敲除通过触发向谷氨酰胺依赖的代谢重编程,损害了线粒体功能、抗肿瘤疗效以及NK细胞的记忆样表型。Ndufa9缺陷NK细胞中α-酮戊二酸/琥珀酸比值的降低,通过在关键免疫功能基因上诱导转录抑制性组蛋白标记H3K27me3,介导了广泛的表观遗传重编程。白藜芦醇介导的NDUFA9激活或其过表达通过恢复复合物I活性增强了NK细胞的抗GBM功能。总之,这些发现揭示了线粒体复合物I活性在NK细胞中的关键作用,并强调其作为可操作靶点以增强GBM患者NK细胞免疫治疗的潜力。意义:本研究揭示线粒体复合物I中NDUFA9缺陷损害了GBM中NK细胞的代谢适应性并削弱了其抗肿瘤活性。我们鉴定出线粒体复合物I亚基NDUFA9作为GBM中NK细胞免疫治疗的关键药理学可靶向节点,利用代谢重编程增强抗肿瘤疗效。参见Tiberti等人的相关评论,第1727页。

展开英文摘要原文

UNLABELLED: Despite successful immuno-oncology therapies in other cancers, they have largely failed in glioblastoma (GBM). In this study, natural killer (NK) cells from patients with glioma show impaired oxidative phosphorylation and mitochondrial complex I activity. Multiomics profiling identified complex I subunit NDUFA9 as a critical mediator of NK cell metabolic fitness. The abundance of NDUFA9+ NK cells informed patient outcomes. Ndufa9 knockout in NK cells compromised mitochondrial function, antitumor efficacy, and the memory-like phenotype of NK cells by triggering a metabolic reprogramming toward glutamine dependence. The decreased α-ketoglutarate/succinate ratio in Ndufa9-deficient NK cells mediated widespread epigenetic reprogramming by inducing the transcriptionally repressive histone mark H3K27me3 on key immune function genes. Resveratrol-mediated NDUFA9 activation or its overexpression enhanced NK cell anti-GBM function by restoring complex I activity. Together, these findings reveal the critical role of mitochondrial complex I activity in NK cells and highlight its potential as an actionable target to enhance NK cell-based immunotherapy for patients with GBM. SIGNIFICANCE: This study reveals that NDUFA9 deficiency in mitochondrial complex I compromises metabolic fitness and impairs the antitumor activity of NK cells in GBM. We identify the mitochondrial complex I subunit NDUFA9 as a key pharmacologically targetable node for NK cell-based immunotherapy in GBM, leveraging metabolic reprogramming to enhance antitumor efficacy. See related commentary by Tiberti et al., p. 1727.

论文信息

作者
Zhou N、Fei F、Tang L、Zhang P、Wang W、Zheng B、Shen Q、Yue J
单位
Department of Neurosurgery, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University and Collaborative Innovation Center, Chengdu, P. R. China.China
期刊
Cancer discovery2026 Sep 1
原文标识
PubMed 41944586 · DOI 10.1158/2159-8290.CD-25-0643